TWST

Twist Bioscience Corp (TWST) - Q3 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2025 (Q3 of fiscal year 2025). Twist Bioscience is a synthetic biology company utilizing silicon-based DNA synthesis technology. The reporting period is marked by a strategic divestiture: on May 2, 2025, the Company sold its DNA Data Storage business to Atlas Data Storage, Inc. ("Atlas"), retaining an equity stake and rights to future milestones and royalties.

Key Financial Metrics

Liquidity: Total cash, cash equivalents, and short-term investments stood at $250.8 million as of June 30, 2025. The Company expects these funds to be sufficient for operations for at least one year.

Material Changes vs. Prior Period

• Revenue Growth: Q3 revenue increased 18% year-over-year, driven by a $11.9 million increase in NGS tools revenue and a $2.7 million increase in synthetic genes revenue. Customer count rose to approximately 2,484.
• Profitability Shift: The Company reported a net income of $20.4 million in Q3 2025, a reversal from the $85.6 million net loss in Q3 2024. This improvement is primarily due to a $48.8 million gain on the sale of the DNA Data Storage business and the absence of the $44.9 million impairment charge recorded in the prior year.
• Expense Management: R&D expenses decreased 20% to $18.0 million, largely due to the transition of DNA data storage employees to Atlas. SG&A expenses increased 12% to $63.4 million, driven by higher stock-based compensation and personnel costs.
• Margin Expansion: Gross margin improved to 53.4% from 43.3% due to revenue growth and flat manufacturing costs.

Guidance, Outlook, and Risks

• Strategic Focus: Management intends to focus on core synthetic biology and biopharma services, leveraging the Wilsonville, Oregon manufacturing facility. The sale of the data storage business was executed to unlock value and allow both entities to focus on their unique markets.
• Financing Activity: In October 2024, the Company entered a Royalty Purchase Agreement with XOMA (US) LLC, receiving $15.0 million upfront in exchange for half of future milestone and royalty payments from specific biopharma agreements. This is recorded as a liability.
• Legal Proceedings: A securities class action lawsuit (Peters v. Twist Bioscience Corporation) remains in the preliminary stage. The Company is awaiting a judge's decision on a motion to dismiss filed in December 2023. A related derivative action is stayed pending the outcome of the class action.
• Risk Factors: Key risks include the ability to increase revenue growth, manage capital requirements, protect intellectual property, and the impact of the pending litigation. The Company has an accumulated deficit of $1.29 billion.

Investor Verification Checklist

• Sustainability of Q3 Profitability: Verify if the $20.4 million net income is sustainable without the one-time $48.8 million gain from the Atlas sale.
• Atlas Transaction Terms: Review the specific terms of the contingent milestone payments (up to $75 million) and royalty structure with Atlas Data Storage.
• XOMA Liability Amortization: Monitor the effective interest rate and amortization schedule for the $15 million liability related to the sale of future revenue.
• Legal Exposure: Track the status of the Peters securities class action lawsuit and the potential financial impact of an unfavorable ruling.
• Operating Cash Flow: Note that net cash used in operating activities was $35.8 million for the nine months ended June 30, 2025, indicating continued cash burn from core operations despite the net income.